VUSE - ETF AI Analysis
Top Page
Vident Core US Equity Fund (VUSE)
VUSE, the Vident Core US Equity Fund, has a solid overall rating driven mainly by its large positions in high-quality companies like Alphabet, Microsoft, and Apple, which benefit from strong financial performance and growth in AI, cloud, and services. The fund also gains support from stable names like Walmart and Johnson & Johnson, though holdings such as Visa and Nvidia face bearish technical signals and high valuations that can limit upside. A key risk is the fund’s heavy exposure to big U.S. technology and growth-oriented companies, which can make performance more sensitive to shifts in tech sentiment and valuation pressures.
VUSE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 671.66M
- Region
- North America
- Expense Ratio
- 0.50%
- Beta
- 0.97
- Issuer
- Vident
- Inception Date
- Jan 21, 2014
- Dividend Yield
- 0.33%
- Asset Class
- Equity
- Index Tracked
- Vident Core U.S. Stock Index
VUSE Summary
VUSE, the Vident Core US Equity Fund, is an ETF that follows the Vident Core U.S. Stock Index and aims to give broad exposure to the overall U.S. stock market. It holds many types of companies, from smaller growth names to large, established firms. Well-known holdings include Apple, Microsoft, Alphabet (Google), and Walmart, spread across technology, health care, consumer, and other sectors. Someone might invest in VUSE for simple, one-stop diversification across many U.S. companies and the potential for long-term growth of the American economy. A key risk is that the fund’s value can rise or fall with the U.S. stock market, especially tech stocks.
How much will it cost me?
This ETF has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because VUSE is more actively managed, using proprietary factors rather than simply tracking a basic market index.
What would affect this ETF?
VUSE could benefit if the U.S. economy stays healthy, technology and healthcare companies continue to grow, and major holdings like Eli Lilly, Meta, Alphabet, Apple, Microsoft, Nvidia, and Amazon keep innovating and gaining market share. On the downside, a U.S. recession, higher interest rates, tighter regulations on big tech or healthcare, or broad market weakness would likely hurt this fund given its strong focus on U.S. stocks and growth-oriented sectors.
VUSE Top 10 Holdings
VUSE is leaning heavily into U.S. Big Tech and healthcare, with names like Apple, Microsoft, and Nvidia doing much of the heavy lifting. Apple and Microsoft have been steadily rising, helped by strong demand for services, cloud, and AI, while Eli Lilly and Johnson & Johnson give the fund a healthy dose of defensive strength from the pharma side. On the flip side, Alphabet and Meta have been lagging lately, taking some shine off the tech tilt. Overall, it’s a U.S.-centric story powered by innovation and medicine, with a few mega-cap engines occasionally sputtering.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 3.46% | $23.25M | $1.33T | 67.86% | 72Outperform |
 MU | Micron | 3.22% | $21.65M | $1.00T | 294.96% | 79Outperform |
 GOOGL | Alphabet Class A | 2.56% | $17.21M | $3.41T | -0.58% | 85Outperform |
 WMT | Walmart | 2.86% | $19.22M | $979.90B | 20.82% | 78Outperform |
 AAPL | Apple | 2.83% | $18.98M | $5.03T | 26.98% | 79Outperform |
 META | Meta Platforms | 2.81% | $18.86M | $1.57T | -7.72% | 76Outperform |
 MSFT | Microsoft | 2.73% | $18.36M | $3.88T | -0.73% | 79Outperform |
 V | Visa | 2.70% | $18.12M | $782.42B | 19.87% | 70Outperform |
 NVDA | Nvidia | 2.58% | $17.30M | $4.93T | 0.86% | 76Outperform |
 JNJ | Johnson & Johnson | 2.53% | $17.01M | $657.68B | 44.51% | 78Outperform |
VUSE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VUSE, the sentiment is Negative. The current price of 71.29 is below the 20-day moving average (MA) of 72.83, below the 50-day MA of 72.76, and above the 200-day MA of 69.56, indicating a neutral trend. The MACD of -0.19 indicates Positive momentum. The RSI at 38.99 is Neutral, neither overbought nor oversold. The STOCH value of 37.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VUSE.
VUSE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| VUSE | $71.29 | $81.00(13.62% Upside) | $671.66M | 0.50% | 74Outperform |
 HLAL | $71.52 | $91.44(27.85% Upside) | $972.36M | 0.50% | 76Outperform |
 SEUS | $25.65 | $30.94(20.62% Upside) | $946.37M | 0.30% | 73Outperform |
 BGDV | $31.27 | $37.25(19.11% Upside) | $877.55M | 0.45% | 74Outperform |
 AUSF | $51.89 | $57.31(10.44% Upside) | $902.41M | 0.27% | 71Outperform |
 AAUB | $49.94 | $60.90(21.95% Upside) | $845.51M | 0.10% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VUSE | Vident Core US Equity Fund | 71.29 | 5.48 | 8.32% | |
| HLAL | Wahed FTSE USA Shariah ETF | 71.52 | 10.37 | 16.96% | |
| SEUS | SEI QiM U.S. Equity Factor Allocation Active ETF | 25.65 | 0.39 | 1.53% | |
| BGDV | Bahl & Gaynor Dividend ETF | 31.27 | 5.03 | 19.16% | |
| AUSF | Global X Adaptive U.S. Factor ETF | 51.89 | 8.17 | 18.69% | |
| AAUB | Alpha Architect US Equity 4 ETF | 49.94 | 0.45 | 0.91% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.